DHA may prevent age-related dementia.

The risk for dementia, a major contributor to incapacitation and institutionalization, rises rapidly as we age, doubling every 5 y after age 65. Tens of millions of new Alzheimer's disease (AD) and other dementia cases are projected as elderly populations increase around the world, creating a projected dementia epidemic for which most nations are not prepared. Thus, there is an urgent need for prevention approaches that are safe, effective, and affordable. This review addresses the potential of one promising candidate, the (n-3) fatty acid docosahexaenoic acid (DHA), which appears to slow pathogenesis of AD and possibly vascular dementia. DHA is pleiotropic, acting at multiple steps to reduce the production of the beta-amyloid peptide, widely believed to initiate AD. DHA moderates some of the kinases that hyperphosphorylate the tau-protein, a component of the neurofibrillary tangle. DHA may help suppress insulin/neurotrophic factor signaling deficits, neuroinflammation, and oxidative damage that contribute to synaptic loss and neuronal dysfunction in dementia. Finally, DHA increases brain levels of neuroprotective brain-derived neurotrophic factor and reduces the (n-6) fatty acid arachidonate and its prostaglandin metabolites that have been implicated in promoting AD. Clinical trials suggest that DHA or fish oil alone can slow early stages of progression, but these effects may be apolipoprotein E genotype specific, and larger trials with very early stages are required to prove efficacy. We advocate early intervention in a prodromal period with nutrigenomically defined subjects with an appropriately designed nutritional supplement, including DHA and antioxidants.

[1]  K. Yurko-Mauro Cognitive and cardiovascular benefits of docosahexaenoic acid in aging and cognitive decline. , 2010, Current Alzheimer research.

[2]  Rosemary O’Connor,et al.  Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling , 2010, Neurobiology of Aging.

[3]  P. Scheltens,et al.  Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial , 2010, Alzheimer's & Dementia.

[4]  Z. Wszolek,et al.  VASCULAR RISK FACTORS AND DEMENTIA: HOW TO MOVE FORWARD? , 2009, Neurology.

[5]  C. Laiño In Follow‐up Analysis of Clinical Trial, NSAIDs Seem to Preserve Cognitive Function in Patients with Healthy Brains , 2009 .

[6]  G. Cole,et al.  Omega-3 fatty acids and dementia. , 2009, Prostaglandins, leukotrienes, and essential fatty acids.

[7]  H. Vinters,et al.  β-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin , 2009, The Journal of Neuroscience.

[8]  P. Aisen,et al.  A clinical trial of docosahexanoic acid (DHA) for the treatment of Alzheimer's disease , 2009, Alzheimer's & Dementia.

[9]  J. Lindsay,et al.  Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. , 2009, The American journal of clinical nutrition.

[10]  J. Palmblad,et al.  Effects of Omega-3 Fatty Acids on Inflammatory Markers in Cerebrospinal Fluid and Plasma in Alzheimer’s Disease: The OmegAD Study , 2009, Dementia and Geriatric Cognitive Disorders.

[11]  Yaakov Stern,et al.  Contribution of vascular risk factors to the progression in Alzheimer disease. , 2009, Archives of neurology.

[12]  Suzanne Craft,et al.  The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. , 2009, Archives of neurology.

[13]  Yang Dong,et al.  Study of cerebrovascular reserve capacity by magnetic resonance perfusion weighted imaging and photoacoustic imaging. , 2009, Magnetic resonance imaging.

[14]  C. Tzourio,et al.  Vascular risk factors and dementia , 2009, Neurology.

[15]  R. Green,et al.  Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. , 2008, Archives of neurology.

[16]  Takashi Morihara,et al.  Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer's Disease , 2008, Journal of Pharmacology and Experimental Therapeutics.

[17]  P. Rzehak,et al.  Evidence for an association between genetic variants of the fatty acid desaturase 1 fatty acid desaturase 2 (FADS1 FADS2) gene cluster and the fatty acid composition of erythrocyte membranes , 2008, British Journal of Nutrition.

[18]  J. O’Keefe,et al.  Omega-3 fatty acids for cardioprotection. , 2008, Mayo Clinic proceedings.

[19]  B. Griffin How relevant is the ratio of dietary n-6 to n-3 polyunsaturated fatty acids to cardiovascular disease risk? Evidence from the OPTILIP study , 2008, Current opinion in lipidology.

[20]  B. Teter,et al.  Omega-3 Fatty Acid Docosahexaenoic Acid Increases SorLA/LR11, a Sorting Protein with Reduced Expression in Sporadic Alzheimer's Disease (AD): Relevance to AD Prevention , 2007, The Journal of Neuroscience.

[21]  M. Selley A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease , 2007, Neurobiology of Aging.

[22]  R. Leighty,et al.  A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer’s transgenic mice , 2007, Neuroscience.

[23]  H. Tanila,et al.  Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD) , 2007, Neurobiology of Disease.

[24]  Patrick L. McGeer,et al.  NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies , 2007, Neurobiology of Aging.

[25]  Frank M LaFerla,et al.  Dietary Docosahexaenoic Acid and Docosapentaenoic Acid Ameliorate Amyloid-β and Tau Pathology via a Mechanism Involving Presenilin 1 Levels , 2007, The Journal of Neuroscience.

[26]  J. Silverman,et al.  Cardiovascular risk factors for Alzheimer's disease. , 2007, The American journal of geriatric cardiology.

[27]  G. Cole,et al.  The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer’s Disease , 2007, Experimental Gerontology.

[28]  Rhoda Au,et al.  Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. , 2006, Archives of neurology.

[29]  G. Caughey,et al.  Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis. , 2006, The Journal of rheumatology.

[30]  H. Tanila,et al.  Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice , 2006, Neurobiology of Disease.

[31]  A D Roses,et al.  Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease , 2006, The Pharmacogenomics Journal.

[32]  Daniel Normolle,et al.  Dose escalation of a curcuminoid formulation , 2006, BMC complementary and alternative medicine.

[33]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[34]  B. Teter,et al.  Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease , 2006, Nature Neuroscience.

[35]  Denis A. Evans,et al.  Fish consumption and cognitive decline with age in a large community study. , 2005, Archives of neurology.

[36]  Charles N Serhan,et al.  A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. , 2005, The Journal of clinical investigation.

[37]  S. Shaikh,et al.  Docosahexaenoic acid affects cell signaling by altering lipid rafts. , 2005, Reproduction, nutrition, development.

[38]  Zhiming Wen,et al.  Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Takashi Morihara,et al.  Dietary n‐3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease , 2005, The European journal of neuroscience.

[40]  Takashi Morihara,et al.  A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model , 2005, The Journal of Neuroscience.

[41]  Ian J Deary,et al.  Cognitive aging, childhood intelligence, and the use of food supplements: possible involvement of n-3 fatty acids. , 2004, The American journal of clinical nutrition.

[42]  F. Gomez-Pinilla,et al.  Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. , 2004, Journal of neurotrauma.

[43]  Takashi Morihara,et al.  Docosahexaenoic Acid Protects from Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2004, Neuron.

[44]  T. Montine,et al.  Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. , 2004, Chemistry and physics of lipids.

[45]  B. Heude,et al.  Cognitive decline and fatty acid composition of erythrocyte membranes--The EVA Study. , 2003, The American journal of clinical nutrition.

[46]  G. Barceló-Coblijn,et al.  Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  C. Haass,et al.  Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts , 2003, The Journal of cell biology.

[48]  Hee-Yong Kim,et al.  Mechanisms of action of docosahexaenoic acid in the nervous system , 2001, Lipids.

[49]  T. Robbins,et al.  Early Detection and Differential Diagnosis of Alzheimer’s Disease and Depression with Neuropsychological Tasks , 2001, Dementia and Geriatric Cognitive Disorders.

[50]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[51]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[52]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[53]  B. Halliwell,et al.  F4 ‐ Isoprostanes as Specific Marker of Docosahexaenoic Acid Peroxidation in Alzheimer's Disease , 1999, Journal of neurochemistry.

[54]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[55]  W. Strittmatter,et al.  Transthyretin sequesters amyloid beta protein and prevents amyloid formation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[56]  S. Angaji,et al.  Neuroprotective Effects Of Curcumin , 2011 .

[57]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.

[58]  M. Shehata,et al.  Cardiovascular Diabetology Important Genetic Checkpoints for Insulin Resistance in Salt-sensitive (s) Dahl Rats , 2008 .

[59]  S. Rapoport,et al.  n-3 Polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism , 2007, Molecular Psychiatry.